<DOC>
	<DOCNO>NCT00926263</DOCNO>
	<brief_summary>This study primarily evaluate single dose pharmacokinetics CP-751,871 effect QT interval prolongation .</brief_summary>
	<brief_title>A Pharmacokinetic And QT Study Of CP-751,871 In Healthy Subjects</brief_title>
	<detailed_description>This study terminate October 30th , 2009 . While study terminate due adverse event alter benefit/risk ratio healthy subject , finding healthy volunteer consider alter benefit/risk evaluation figitumumab cancer patient . No change due termination study anticipate conduct ongoing cancer patient study figitumumab time .</detailed_description>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Healthy male subject and/or healthy female subject nonchildbearing potential age 18 55 year , inclusive Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . 12lead ECG demonstrate QTc &gt; 450 msec screen clinically significant abnormality screen . History family history risk factor QTc interval prolongation torsades de pointes ( eg , organic heart disease , congestive heart failure , hypokalemia , hypomagnesemia , congenital long QT syndrome , myocardial ischemia infarction ) ; family history sudden death .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>QTc interval prolongation</keyword>
</DOC>